India Expands Accredited Livestock Diagnostics to 28 Tests
India has expanded the accredited testing scope of its national veterinary epidemiology institute to 28 diagnostic tests spanning major livestock diseases, zoonoses and antimicrobial resistance. The change is important because animal-health decisions depend not only on having a test, but on whether a laboratory has demonstrated competence to perform that specific method under a controlled quality system.
The Indian Council of Agricultural Research announced on 16 October 2026 that the National Institute of Veterinary Epidemiology and Disease Informatics in Bengaluru had expanded its scope under ISO/IEC 17025:2017. The revised scope was approved on 7 October and remains valid until 4 December 2029, subject to continued compliance with National Accreditation Board for Testing and Calibration Laboratories requirements.
What the 28-test scope covers
The accredited scope reaches across cattle, buffaloes, sheep, goats, pigs, dogs and poultry. For cattle and buffaloes, ICAR lists brucellosis, leptospirosis, capripoxvirus infections—including lumpy skin disease—trypanosomosis and bovine tuberculosis. Sheep and goat coverage includes peste des petits ruminants, sheep pox, goat pox, brucellosis and leptospirosis.
For pigs, the scope includes African swine fever, classical swine fever, brucellosis and leptospirosis. Leptospirosis testing in dogs is also covered. The institute’s bacterial work includes identification and antimicrobial-susceptibility testing for Escherichia coli and Staphylococcus species in specified livestock and poultry samples.
The methods are not all interchangeable. The announcement identifies polymerase chain reaction, real-time PCR, enzyme-linked immunosorbent assay, virus neutralisation, microbiological identification and antimicrobial-susceptibility testing. Each method answers a different diagnostic question: detecting pathogen genetic material, measuring antibodies, isolating or identifying organisms, or determining whether bacteria remain susceptible to particular antimicrobials.
Accreditation is specific evidence—not a blanket guarantee
NABL explains that laboratory accreditation provides formal recognition of technical competence for a defined scope. It is therefore narrower and more useful than a general claim that a laboratory is “high quality.” The recognition applies to listed tests, sample types and methods, under the conditions assessed by the accreditation body. NABL’s own explanation of laboratory accreditation emphasises this competence-based purpose.
That does not mean every suspected outbreak will be detected quickly. Diagnostic performance still depends on when samples are collected, whether the correct tissue or fluid is submitted, cold-chain and transport conditions, geographic access, laboratory throughput, reagent availability and the sensitivity and specificity of the chosen assay. Accreditation strengthens confidence in the testing step; it does not repair weaknesses before or after the sample reaches the laboratory.
Nor does an accredited negative result prove that a herd, district or country is disease-free. Surveillance design determines what population has actually been sampled and how much undetected infection could remain. Disease freedom, trade certification and outbreak control require epidemiological interpretation alongside laboratory results.
Why the disease mix matters for livestock production
The scope combines fast-moving transboundary diseases with chronic zoonoses and production-limiting infections. African swine fever and classical swine fever can trigger heavy pig losses and movement restrictions. Peste des petits ruminants affects sheep and goats, which are especially important to smallholders. Lumpy skin disease disrupts cattle production through illness, mortality, lower milk output and trade controls. Brucellosis, leptospirosis and bovine tuberculosis link livestock productivity with occupational and public-health risk.
Putting these tests within an assessed quality framework can make surveillance data more comparable over time and more defensible when authorities decide whether to impose, maintain or lift control measures. It can also reduce the risk that inconsistent laboratory practice obscures a real change in disease prevalence. The economic value comes from better decisions, not from the accreditation certificate by itself.
The antimicrobial-resistance component adds a different form of production intelligence. Identifying E. coli or Staphylococcus is only the first step; susceptibility testing helps show which drugs are likely to work against the isolate tested. Aggregated carefully, such results can support treatment guidance and stewardship. They should not be read as permission for routine antimicrobial use without veterinary diagnosis, because resistance patterns vary by organism, location, sample and time.
The expansion builds on an existing diagnostic role
ICAR-NIVEDI previously documented NABL recognition for laboratories working on PPR and animal leptospirosis. A 2023 institute note described those laboratories’ surveillance, diagnostic support and capacity-building role. The 2026 announcement broadens the range of specified livestock tests under accreditation, but it does not provide a before-and-after count that supports describing the change as a precise multiple.
The new scope also should not be mistaken for a national inventory of all accredited veterinary testing in India. Other public, university and private laboratories operate in the country, and the ICAR announcement concerns one institute’s assessed scope. National resilience depends on how reference and specialist laboratories connect with state facilities, field veterinarians and sample-collection networks.
What producers and disease-control teams should watch
Turnaround times by disease and sample type, particularly during suspected outbreaks when demand rises sharply.
The number and geographic origin of samples tested, which would show whether the accredited capacity is reaching major livestock regions.
Participation in proficiency testing and continued compliance through the accreditation period ending in December 2029.
How test results feed into official surveillance, movement controls, vaccination strategy and outbreak reports.
Whether antimicrobial-susceptibility data are aggregated into usable regional guidance while protecting farm and patient confidentiality.
Investment in field sampling, cold-chain logistics and state-level laboratory links, without which central technical competence has limited reach.
For farmers, the practical promise is not that 28 accredited tests will eliminate disease. It is that a wider range of high-consequence suspicions can be investigated through methods whose technical competence has been independently assessed. The production impact will depend on whether that capability is converted into faster sampling, reliable reporting and proportionate control decisions.
Methodology and limitations
Agrilinkage reviewed ICAR’s 16 October announcement, NABL’s description of laboratory accreditation and ICAR-NIVEDI’s earlier note on its PPR and leptospirosis laboratories. Disease effects are presented as general production and surveillance implications; the article does not infer current outbreak prevalence from the accreditation decision.
The public announcement lists disease groups and laboratory techniques but does not publish test-by-test throughput, prices, turnaround times, staffing, historical error rates or sample-access data. Those missing operational indicators are necessary before the expansion’s real-world surveillance impact can be measured.
Comments